Asset
LESINURAD
Ironwood Pharmaceuticals Inc. Class A Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03226899 | phase4 | terminated | 2017-07-19 | 2019-02-25 | Ironwood Pharmaceuticals, Inc. | A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 207988 | NDA | IRONWOOD PHARMACEUTICALS INC |
| NDA 209203 | NDA | IRONWOOD PHARMACEUTICALS INC |
Marketed products (3)
- DUZALLO
- DUZALLO
- ZURAMPIC